Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer

• Material Type: 博士論文
• Title: Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer
• Author/Editor: Kohmoto, Tomohiro; Masuda, Kiyoshi; Shoda, Katsutoshi; Takahashi, Rizu; Ujiro, Sae; Tange, Shoichiro; Ichikawa, Daisuke; Otsuji, Eigo; Imoto, Issei
• Author Heading: Kohmoto, Tomohiro; Masuda, Kiyoshi; Shoda, Katsutoshi; Takahashi, Rizu; Ujiro, Sae; Tange, Shoichiro; Ichikawa, Daisuke; Otsuji, Eigo; Imoto, Issei
• Publication, Distribution, etc.: The International Gastric Cancer Association|The Japanese Gastric Cancer Association|Springer naure
• Publication Date: 2019-10-25
• Publication Date (W3CDTF): 2019-10-25
• Alternative Title: Claudin-6は、腸型胃がんの亜群において独立した予後因子であるとともにがん促進遺伝子として機能する
• Periodical title: Gastric Cancer
• No. or year of volume/issue: 23 3
• Volume: 23
• Issue: 3
• Pages: 403-417
• ISSN (Periodical Title): ISSN : 1436-3305; ISSN : 1436-3291
• Degree grantor/type: 徳島大学
• Date Granted: 2020-03-23
• Dissertation Number: 甲第3356号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: Claudin-6; Stomach; Neoplasms; Prognosis; Computer-simulation; Oncogenes; Stomach neoplasms
• Target Audience: 一般
• Note (General): Background We aimed to identify novel tumor-promoting drivers highly expressed in gastric cancer (GC) that contribute to worsened prognosis in affected patients. Methods Genes whose expression was increased and correlated with worse prognosis in GC were screened using datasets from the Cancer Genome Atlas and Gene Expression Omnibus. We examined Claudin-6 (CLDN6) immunoreactivity in GC tissues and the effect of CLDN6 on cellular functions in GC cell lines. The mechanisms underlying GC-promoting function of CLDN6 were also investigated. Results CLDN6 was identified as a gene overexpressed in GC tumors as compared with adjacent non-tumorous tissues and whose increased expression was positively correlated with worse overall survival of GC patients, particularly those with Lauren’s intestinal type GC, in data from multiple publicly available datasets. Additionally, membranous CLDN6 immunoreactivity detected in intestinal type GC tumors was correlated with worse overall survival. In CLDN6-expressing GC cells, silencing of CLDN6 inhibited cell proliferation and migration/invasion abilities, possibly via suppressing transcription of YAP1 and its downstream transcriptional targets at least in part. Conclusions: This study identified CLDN6 as a GC-promoting gene, suggesting that CLDN6 to be a possible single prognostic marker and promising therapeutic target for a subset of GC patients.
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.1007/s10120-019-01014-x
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ

Table of Contents

https://repo.lib.tokushima-u.ac.jp/files/public/11/114707/20200507105231996893/k3356_abstract_review.pdf fulltext

https://repo.lib.tokushima-u.ac.jp/files/public/11/114707/20201026132005377243/k3356_fulltext.pdf fulltext